CD55在结肠癌中表达调控的研究进展

刘佳 伟1, 张 帆2, 侯俊 志1, 张 志1
1.华北理工大学附属唐山市工人医院肿瘤科 唐山 063000；2.河北医科大学附属唐山市工人医院肿瘤科 唐山 063000

摘要

目的：癌症是涉及全球范围的重大健康问题之一，其发病数量持续增长且特征不一。越来越重的疾病负担加诸于中低收入水平的发展中国家，这不仅是人口变化导致的结果，更是风险因素转变造成的影响。根据国际癌症研究机构（IARC）发布的全球癌症2020年统计数据（GLOBOCAN2020）显示，结直肠癌（CRC）目前居全球发病谱第三位和死因谱第二位[1]，并且全球癌症的发病和死亡负担仍在增长[2,3]。因而重视恶性肿瘤的一级预防显得尤为重要，结直肠癌发生发展的分子生物学机制的研究对于减少结直肠癌的发病率、降低其死亡率是有意义的。

关键词

CD55；结肠癌；基因表达

参考

[1]SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA: a cancer journal for clinicians,2021, 71(3): 209-49.[2]曹毛毛, 陈万青. GLOBOCAN 2020 全球癌症统计数据解读%J 中国医学前沿杂志(电子版) [J]. 2021, 13(03): 63-9.[3]刘宗超,李哲轩,张阳,et al.2020 全球癌症统计报告解读%J肿瘤综合治疗电子杂志 [J]. 2021,7(02): 1-14.[4]SPENDLOVE I,RAMAGE J M,BRADLEY R, et al. Complement decay accelerating factor (DAF)/CD55 in cancer [J]. Cancer immunology, immunotherapy : CII, 2006, 55(8): 987-95.[5]MORGAN R A,YANG J C,KITANO M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 [J]. Molecular therapy : the journal of the American Society of Gene Therapy,2010, 18(4): 843-51.[6]BRODBECK W G, LIU D, SPERRY J, et al. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor [J].Journal of immunology (Baltimore, Md : 1950), 1996, 156(7): 2528-33.[7]SHANG Y, CHAI N, GU Y, et al. Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer [J]. Archives of pathology&laboratory medicine,2014,138(7):910-9.[8]COUZIN-FRANKEL J. Breakthrough of the year 2013. Cancer immunotherapy [J]. Science (New York, NY), 2013, 342(6165): 1432-3.[9]SIEGEL R L,MILLER K D, FUCHS H E,et al Cancer Statistics,2021[J].CA:a cancer journal for clinicians, 2021, 71(1): 7-33.[10]CéLIND J, OHLSSON C, BYGDELL M, et al. Childhood Body Mass Index Is Associated with Risk of Adult Colon Cancer in Men: An Association Modulated by Pubertal Change in Body Mass Index [J]. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,2019,28(5):974-9.[11]PEDERSEN J K, ROSHOLM J U, EWERTZ M, et al. Declining cancer incidence at the oldest ages: Hallmark of aging or lower diagnostic activity?[J].Journal of geriatric oncology,2019,10(5):792-8.[12]JALILIAN H, ZIAEI M, WEIDERPASS E, et al. Cancer incidence and mortality among firefighters [J]. International journal of cancer, 2019, 145(10): 2639-46.[13]HOFFMANN E M. Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action [J]. Immunochemistry,1969,6(3): 405-19.[14]张艳艳. 膜结合补体调节因子遗传变异与肺癌易感性关系及其机制研究 [D];华北理工大学, 2017.[15]付宁, 仵红娇, 谢俞宁, et al. CD55 启动子区多态性与直肠癌发病风险的研究 %J 实用医学杂志[J].2019,35(18):2886-90.[16]STEINERT M,WOBUS M，BOLTZE C,et al.Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues [J]. The American journal of pathology, 2002, 161(5):1657-67.[17]贾祯贤, 仵红娇, 谢俞宁, et al. CD55 启动子区 rs2564978 多态性影响肝癌遗传易感性%J现代预防医学[J].2020,47(09):1651-5.[18]仵红娇, 高慧,谢俞宁,et al.补体因子 CD55 启动子区多态影响食管癌发病的相关性%J中华预防医学杂志[J]. 2018, 52(08):822-6.[19]MUSTAFA T, KLONISCH T,HOMBACH-KLONISCH S, et al. Expression of CD97 and CD55 in human medullary thyroid carcinomas[J].International journal of oncology,2004,24(2):285-94.[20]WU J, LEI L, WANG S,et al.Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma[J].Journal of biomedicine & biotechnology,2012,2012:587672.